Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: J Neurochem. 2016 Dec 20;140(2):334–346. doi: 10.1111/jnc.13892

Figure 4. Lovastatin-encapsulating PLGA nanoparticles protect against clinical development of EAN.

Figure 4

Five days prior to induction of EAN, male Lewis rats received bilateral (A, B) peri-neural or (C, D) subcutaneous injections of empty-(open symbols & bars) or 25% w/w lovastatin-encapsulating (closed symbols & bars) nanoparticles (20 mg each). Clinical progression of (A, C) EAN and (B, D) body weight were assessed daily. Shown are the mean ± SEM (n=6 per group). *p<0.01, Mann-Whitney non-parametric U-test; #p<0.0001, Student's t-test.